Table 2:

Association between atrial fibrillation (baseline and follow–up) and cognitive and functional outcomes among participants of the ONTARGET and TRANSCEND trials

Outcome	All participants (no atrial fibrillation at baseline), no. % n = 29 916	No atrial fibrillation, no. % n = 27 864	Atrial fibrillation at baseline, no. % n =1 016	New atrial fibrillation at follow-up, no. % n = 2 052	All atrial fibrillation (baseline and follow-up), no. % n = 3 068
Composite outcome*	n = 29 916 7 972 (26.7)	n = 27 864 7 269 (26.1)	n = 1 016 347 (34.1)	n = 2 052 703 (34.3)	n = 3 068 1 050 (34.2)
Decrease in MMSE score ≥ 3	n = 27 003 4 524 (16.8)	n = 25 114 4 169 (16.6)	n = 843 171 (20.3)	n = 1 889 355 (18.8)	n = 2 732 526 (19.3)
Dementia during follow-up	n = 27 386 2 157 (7.9)	n = 25 521 1 972 (7.7)	n = 890 114 (12.8)	n = 1 865 185 (9.9)	n = 2 755 299 (10.9)
Loss of independence in ADL	n = 27 160 2 006 (7.4)	n = 25 272 1 775 (7.0)	n = 857 122 (14.2)	n = 1 888 231 (12.2)	n = 2 745 353 (12.9)
Admission to long-term care	n = 29 070 1 345 (4.6)	n = 27 052 1 183 (4.4)	n = 953 74 (7.8)	n = 2 018 162 (8.0)	n = 2 971 236 (7.9)

Note: ADL = activities of daily living, MMSE = Mini–Mental State Examination.

^*Decrease in MMSE score of 3 points or more, new diagnosis of dementia at follow-up, loss of independence with performing ADL and admission to a long-term care facilty.